F2RL1 and diabetic kidney disease: The application of the PAR-2 inhibitor (GB83) reduced endothelial cell injury and glomerulosclerosis, and this provided the first evidence for the pathogenic role of PAR-2 in DKD (Nikolic-Paterson, 2016).